Aerovate Therapeutics appoints Allison Dorval to Board of Directors

Jade Biosciences, Inc.

Allison Dorval, CFO of Voyager Therapeutics, appointed to Board effective July 15, 2021.
Dorval appointed chair of Audit Committee; Joshua Resnick resigns from Audit Committee.
Maha Katabi steps down as Audit Committee chair but remains a member; Dorval qualifies as independent and financial expert.
Dorval to serve as Class II director until the 2023 annual meeting of stockholders.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Allison Dorval

Director

JBIO · Jade Biosciences, Inc.

Effective: 2021-07-15
Filed: July 19, 2021, 7:59 PM ET

the Board appointed Allison Dorval as a member of the Board, effective as of July 15, 2021

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Allison Dorval was appointed as Director at Jade Biosciences, Inc..

Action: appointed
Role: Director

Exact text from the filing

the Board appointed Allison Dorval as a member of the Board, effective as of July 15, 2021

View on SEC.gov

Jade Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-21-093268

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.